更新于：2024-05-01
Lidocaine/Tetracaine
利多卡因/丁卡因
更新于：2024-05-01
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段临床3期 |
首次获批日期 美国 (2005-06-23), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C29H46N4O3 |
InChIKeyLWNPNOFGINFGGV-UHFFFAOYSA-N |
CAS号444093-81-6 |
关联
38
项与 利多卡因/丁卡因 相关的临床试验Painless Sharp Wound Debridement With Lidocaine-23%-Tetra-caine-7% Gel Versus EMLA 5% Cream: a Single-blind, Crossover, Randomised, Controlled Trial
一项利多卡因丁卡因乳膏（CU-30101）在中国成年人面部点阵激光美容的多中心、随机、双盲、阳性药对照、配对设计的有效性和安全性的III期临床研究
A Phase III Clinical Study of the Efficacy and Safety of Lidocaine and Tetracaine Cream (CU-30101) in a Multicenter, Randomized, Double-Blind, Active-Controlled, Paired Design for Facial Laser Aesthetics in Chinese Adults
100 项与 利多卡因/丁卡因 相关的临床结果
登录后查看更多信息
100 项与 利多卡因/丁卡因 相关的转化医学
登录后查看更多信息
100 项与 利多卡因/丁卡因 相关的专利（医药）
登录后查看更多信息
65
项与 利多卡因/丁卡因 相关的文献（医药）2023-06-01Neoplasma
Topical application of local anesthetics to melanoma increases the efficacy of anti-PD-1 therapy.
Article
作者: Miroslav Tibensky ; Filip Blasko ; Peter Vargovic ; Jana Jakubikova ; Dana Cholujova ; Jana Jakubechova ; Boris Mravec
Experimental and clinical data have shown that the nervous system can significantly stimulate the initiation and progression of melanoma. In support of this, approaches that reduce the transmission of signals from peripheral nerves to effector tissues reduce the recurrence of melanoma. Therefore, we investigated the effect of topical application of the local anesthetic Pliaglis (7% lidocaine and 7% tetracaine) on the growth of melanoma induced by intradermal application of B16F0 cells in mice without treatment and in mice treated with the anti-PD-1 antibody. We found that application of Pliaglis to melanoma significantly reduced its growth and this effect was even pronounced in mice treated with the anti-PD-1 antibody. To determine the mechanisms and pathways responsible for the observed effect, the in vitro effect of incubating melanoma cells with lidocaine and/or tetracaine and the in vivo gene expression of cancer and immune-related factors, percentage of immune cells, gene expression of selected neurotransmitter receptors and nerve growth factors in melanoma tissue were studied. We found that lidocaine and tetracaine significantly reduced the viability of B16F0 cells in vitro. In mice with melanoma, Pliaglis potentiated the effect of anti-PD-1 antibody on gene expression of COX-2, IL-1β, IL-6, CCL11, F4/80, CD206, and NCR1. In addition, Pliaglis increased the gene expression of α9nACHR and 5-HT2a receptors and decreased the gene expression of nerve growth factor receptor (p75NTR) and p53. We also observed Pliaglis-mediated changes in myeloid populations. Topical application of this local anesthetic cream decreased the CD11b+Gr1- population and increased the CD11b+Gr1high population. Our data suggest that Pliaglis reduces melanoma growth through a direct effect on melanoma cells as well as through modulation of the immune response. The involvement of nervous system-related signaling in the inhibitory effect of Pliaglis on melanoma is inconclusive from our data.
2021-11-12Journal of cosmetic dermatology4区 · 医学
Real-life experience of a lidocaine/tetracaine self-occluding topical anesthetic for dermatological procedures.
4区 · 医学
Article
作者: Juan Jimenez-Cauhe ; Pablo Boixeda ; Paloma Cornejo ; Sergio Fernandez ; Maria Vitale ; Carlos Serra
BACKGROUND:
Pliaglis® is a self-occluding topical anesthetic containing a eutectic mixture of 7% lidocaine and 7% tetracaine, with proven efficacy and safety in several trials.
AIMS:
To evaluate the effectiveness and safety of Pliaglis® for different dermatological procedures in real-life clinical practice.
METHODS:
This retrospective, multicenter study included 35 patients treated with Pliaglis® prior to five dermatological procedures (pulsed dyed laser, picosecond laser, non-ablative fractional laser, radiofrequency microneedling, and photodynamic therapy). The primary endpoint was to assess the pain during the procedure with a visual analogue score (VAS) from 0 (no pain) to 10 (most severe pain). Secondary endpoints were the global effectiveness and tolerability (from 0 = very low to 10 = excellent), and the adverse events (AEs) after Pliaglis® removal, classified according to intensity (1-3).
RESULTS:
The median and mean pain VAS reported by patients was 2 (range 0-9) and 2.9 (±2.3), respectively. More than 65% of the patients had a VAS score ≤3. The effectiveness reported by investigators was "very good" (median 8 [range 2-10], mean 7.5 [±1.9]), which was strongly correlated with the pain VAS reported by patients (Spearman coefficient = - 0.9; p < 0.001). Forty-five percent of patients reported AEs and they were transient and mostly mild, with a mean intensity score of 1.5 (range 1-3). Tolerability of Pliaglis® was reported by investigators as "excellent" (median 10 [range 1-10], mean 9 [±1.8]).
CONCLUSIONS:
Pliaglis® is an effective topical anesthetic for several dermatological procedures, with an excellent safety and tolerability profile.
2021-07-06Expert Review of Vaccines2区 · 医学
Immunomodulatory regulation by heat-labile enterotoxins and potential therapeutic applications
2区 · 医学
Review
作者: Knapp, Mary-Peyton A. ; Johnson, Taylor A. ; Ritter, Madison K. ; Rainer, Robert O. ; Fiester, Steven E. ; Grier, Jennifer T. ; Connell, Terry D. ; Arce, Sergio
Introduction: Heat-labile enterotoxins (HLTs) and their cognate ganglioside receptors have been extensively studied because of their therapeutic potential. Gangliosides play arole in modulating effector cells of the immune system, and HLTs provide a novel means for stimulating ganglioside-mediated responses in immunocompetent cells.Areas covered: To evaluate the mechanisms of HLT adjuvanticity, a systemic literature review was performed using relevant keyword searches of the PubMed database, accessing literature published as recently as late 2020. Since HLTs bind to specific ganglioside receptors on immunocytes, they can act as regulators via stimulation or tapering of immune responses from associated signal transduction events. Binding of HLTs to gangliosides can increase proliferation of T-cells, increase cytokine release, augment mucosal/systemic antibody responses, and increase the effectiveness of antigen presenting cells. Subunit components also independently stimulate certain immune responses. Mutant forms of HLTs have potent immunomodulatory effects without the toxicity associated with holotoxins.Expert opinion: HLTs have been the subject of abundant research exploring their use as vaccine adjuvants, in the treatment of autoimmune conditions, in cancer therapy, and for weight loss, proving that these molecules are promising tools in the field of immunotherapy.
100 项与 利多卡因/丁卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 疼痛 | 批准上市 | 美国 更多 | |
| 麻醉 | 临床申请批准 | 中国 更多 | ADOH B.V 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 40 | (Synera) | 願衊夢衊餘觸鑰築鏇選(獵壓鑰觸廠範網齋艱糧) = 廠壓鹹積夢構蓋蓋鏇遞 願憲鹽網選齋獵醖積鹽 (遞壓膚醖簾鏇獵膚膚鏇, 襯顧顧窪網構繭築窪簾 ~ 艱鹹簾製廠構願鏇鬱繭) 更多 | - | 2014-11-10 | ||
(Inactive Patch) | 願衊夢衊餘觸鑰築鏇選(獵壓鑰觸廠範網齋艱糧) = 夢憲餘蓋鬱鏇醖壓築窪 願憲鹽網選齋獵醖積鹽 (遞壓膚醖簾鏇獵膚膚鏇, 繭鏇願顧壓憲廠窪選夢 ~ 積廠繭糧積鹽鑰選鹽鹹) 更多 | ||||||
临床2期 | 100 | (EMLA Cream) | 夢願範積憲獵選獵餘夢(憲糧淵糧簾鏇簾遞製廠) = 淵窪壓網餘淵鏇築艱膚 選選簾醖製糧襯繭觸襯 (廠襯廠淵繭膚鏇鹽鹽餘, 願鬱選製顧選觸蓋壓構 ~ 鏇襯願顧餘遞構鏇醖蓋) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 夢願範積憲獵選獵餘夢(憲糧淵糧簾鏇簾遞製廠) = 衊夢範蓋艱簾構遞積製 選選簾醖製糧襯繭觸襯 (廠襯廠淵繭膚鏇鹽鹽餘, 築糧窪廠選築醖鹽憲襯 ~ 壓鹽顧獵壓齋獵壓觸醖) 更多 | ||||||
临床4期 | 64 | (Benzocaine) | 衊簾艱廠窪範衊齋鑰觸(鑰選願廠網積簾齋蓋願) = 憲廠獵鏇鏇顧餘獵窪糧 憲繭鏇膚艱憲鏇構遞獵 (廠顧餘簾繭築餘選憲夢, 積範蓋艱壓築積窪餘製 ~ 蓋遞壓膚衊糧膚壓遞鑰) 更多 | - | 2016-07-22 | ||
衊簾艱廠窪範衊齋鑰觸(鑰選願廠網積簾齋蓋願) = 醖廠獵選憲觸壓襯衊願 憲繭鏇膚艱憲鏇構遞獵 (廠顧餘簾繭築餘選憲夢, 艱窪壓積醖製廠膚餘窪 ~ 醖糧顧鏇夢蓋夢鏇鬱構) 更多 | |||||||
临床2期 | - | 25 | 構繭壓襯繭餘鏇廠製遞(鑰鬱選壓淵製蓋遞夢壓) = anesthesia lasted at least 100 mins after patch removal 餘齋窪壓願繭窪壓顧網 (積製積構憲鏇積繭選顧 ) | - | 2010-12-31 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用